2059-7029

ESMO Open

Elsevier

View prefix report (10.1016)

Health Score

0 Poor

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Add abstracts to 8297 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

High impact8297 DOIs
2

Attach ORCID iDs across 7218 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

High impact7218 DOIs
3

Deposit reference lists for 6140 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

High impact6140 DOIs

DOIs for this ISSN

Showing the top 5 of 8297 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 ESMO / ASCO Recommendations for a Global Curriculum in Medic… (10.1136/esmoopen-2016-000097)
Abstract References ORCID
147.28 91
2 LBA1 Durvalumab in combination with chemoradiotherapy for pa… (10.1016/j.esmoop.2024.102986)
Abstract References ORCID
137.91 68
3 Multiple primary tumours: challenges and approaches, a revie… (10.1136/esmoopen-2017-000172)
Abstract ORCID
135.84 520
4 Cancer cachexia in adult patients: ESMO Clinical Practice Gu… (10.1016/j.esmoop.2021.100092)
Abstract ORCID
133.60 469
5 Mechanisms of resistance to EGFR-targeted drugs: lung cancer (10.1136/esmoopen-2016-000060)
Abstract ORCID
128.99 379
6 Real-world application of tumor mutational burden-high (TMB-… (10.1016/j.esmoop.2021.100336)
Abstract ORCID
125.33 320
7 Implementing TMB measurement in clinical practice: considera… (10.1136/esmoopen-2018-000442)
Abstract ORCID
124.14 303
8 Adolescents and young adults (AYA) with cancer: a position p… (10.1016/j.esmoop.2021.100096)
Abstract ORCID
120.24 253
9 Cancer and liver cirrhosis: implications on prognosis and ma… (10.1136/esmoopen-2016-000042)
Abstract ORCID
119.19 241
10 Anxiety and depression in adult cancer patients: ESMO Clinic… (10.1016/j.esmoop.2023.101155)
Abstract ORCID
119.01 239
11 Pooled analysis of drug-related interstitial lung disease an… (10.1016/j.esmoop.2022.100554)
Abstract ORCID
118.92 238
12 Descriptive statistical analysis of a real life cohort of 24… (10.1136/esmoopen-2015-000024)
Abstract ORCID
116.01 208
13 Drug-induced interstitial lung disease during cancer therapi… (10.1016/j.esmoop.2022.100404)
Abstract ORCID
115.80 206
14 Cardiotoxicity of immune checkpoint inhibitors (10.1136/esmoopen-2017-000247)
Abstract ORCID
115.48 203
15 Salivary gland cancer: ESMO–European Reference Network on Ra… (10.1016/j.esmoop.2022.100602)
Abstract ORCID
113.24 183
16 Care of the adult cancer patient at the end of life: ESMO Cl… (10.1016/j.esmoop.2021.100225)
Abstract ORCID
112.88 180
17 Epithelioid hemangioendothelioma, an ultra-rare cancer: a co… (10.1016/j.esmoop.2021.100170)
Abstract ORCID
112.03 173
18 Targeting HER2 in non-small-cell lung cancer (NSCLC): a glim… (10.1016/j.esmoop.2021.100260)
Abstract ORCID
111.65 170
19 Comprehensive clinical and molecular characterization of cla… (10.1016/j.esmoop.2022.100762)
Abstract ORCID
110.48 161
20 The management of hepatocellular carcinoma. Current expert o… (10.1016/j.esmoop.2023.101567)
Abstract ORCID
109.93 157
21 Predictive role of microsatellite instability for PD-1 block… (10.1016/j.esmoop.2020.100036)
Abstract ORCID
109.79 156
22 Safety and activity of IT-139, a ruthenium-based compound, i… (10.1136/esmoopen-2016-000154)
Abstract ORCID
108.80 149
23 First-line nivolumab plus ipilimumab with two cycles of chem… (10.1016/j.esmoop.2021.100273)
Abstract ORCID
108.51 147
24 Anti-TIGIT therapies for solid tumors: a systematic review (10.1016/j.esmoop.2023.101184)
Abstract ORCID
107.77 142
25 2023 MASCC and ESMO guideline update for the prevention of c… (10.1016/j.esmoop.2023.102195)
Abstract ORCID
107.61 141
26 Challenge of cancer in the elderly (10.1136/esmoopen-2015-000020)
Abstract ORCID
107.15 138
27 Recurrent or primary metastatic cervical cancer: current and… (10.1016/j.esmoop.2022.100579)
Abstract ORCID
106.84 136
28 Leptomeningeal metastasis from solid tumours: EANO–ESMO Clin… (10.1016/j.esmoop.2023.101624)
Abstract ORCID
106.84 136
29 Integrating next-generation sequencing into clinical oncolog… (10.1136/esmoopen-2016-000094)
Abstract ORCID
106.84 136
30 Targeting immune checkpoints in breast cancer: an update of… (10.1136/esmoopen-2017-000255)
Abstract ORCID
106.84 136
31 Activating HER2 mutations as emerging targets in multiple so… (10.1136/esmoopen-2017-000279)
Abstract ORCID
106.36 133
32 How I treat biliary tract cancer (10.1016/j.esmoop.2021.100378)
Abstract ORCID
105.86 130
33 Evolution of overall survival and receipt of new therapies b… (10.1016/j.esmoop.2021.100114)
Abstract ORCID
105.53 128
34 The role of homologous recombination deficiency testing in o… (10.1016/j.esmoop.2021.100144)
Abstract ORCID
105.36 127
35 Tumour-infiltrating lymphocytes are correlated with higher e… (10.1136/esmoopen-2016-000150)
Abstract ORCID
105.36 127
36 How shall we treat early triple-negative breast cancer (TNBC… (10.1136/esmoopen-2018-000357)
Abstract ORCID
104.85 124
37 Optimizing treatment management of trastuzumab deruxtecan in… (10.1016/j.esmoop.2022.100553)
Abstract ORCID
104.67 123
38 Prospective experimental treatment of colorectal cancer pati… (10.1016/j.esmoop.2021.100103)
Abstract ORCID
104.50 122
39 Beyond epidermal growth factor receptor: MET amplification a… (10.1016/j.esmoop.2021.100319)
Abstract ORCID
102.85 113
40 The prognostic impact of tumor mutational burden (TMB) in th… (10.1016/j.esmoop.2021.100124)
Abstract ORCID
102.46 111
41 Atezolizumab plus bevacizumab versus lenvatinib or sorafenib… (10.1016/j.esmoop.2022.100591)
Abstract ORCID
102.27 110
42 Severe steroid-resistant anti-PD1 T-cell checkpoint inhibito… (10.1136/esmoopen-2017-000268)
Abstract ORCID
102.27 110
43 LBA1 Final analysis of the placebo-controlled randomised pha… (10.1016/j.esmoop.2023.101571)
Abstract References ORCID
102.13 22
44 4O First-line (1L) osimertinib (osi) ± platinum-pemetrexed i… (10.1016/j.esmoop.2024.102583)
Abstract References ORCID
102.13 22
45 A prospective cohort study on the safety of checkpoint inhib… (10.1016/j.esmoop.2020.100042)
Abstract ORCID
102.07 109
46 Sex and gender perspectives in colorectal cancer (10.1016/j.esmoop.2023.101204)
Abstract ORCID
101.67 107
47 Artificial intelligence for detection of microsatellite inst… (10.1016/j.esmoop.2022.100400)
Abstract ORCID
101.27 105
48 Recommendations for a practical implementation of circulatin… (10.1016/j.esmoop.2022.100399)
Abstract ORCID
100.64 102
49 The molecular profiling of solid tumors by liquid biopsy: a… (10.1016/j.esmoop.2021.100164)
Abstract ORCID
100.22 100
50 Biosimilars: a position paper of the European Society for Me… (10.1136/esmoopen-2016-000142)
Abstract ORCID
100.22 100